B Johari1,2, F Maghsood3,4, H Madanchi5,6, M Moradi7,8, M Kadivar3. 1. Cancer Gene Therapy Research Center, Zanjan University of Medical Sciences, Zanjan, Iran. 2. Department of Medical Biotechnology, School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran. 3. Department of Biochemistry, Pasteur Institute of Iran, Tehran, Iran. 4. Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran. 5. Department of Biotechnology, School of Medicine, Semnan University of Medical Sciences, Semnan, Iran. 6. Drug Design and Bioinformatics Unit, Department of Medical Biotechnology, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran. 7. Department of Biotechnology, Faculty of Biological Science and Technology, University of Isfahan, Isfahan, Iran. 8. Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran.
Abstract
AIMS: This study was done to investigate the anti-inflammatory effects of high molecular weight secretions from Limosilactobacillus reuteri PTCC 1655 probiotic bacteria on lipopolysaccharide (LPS)-stimulated phorbol 12-myristate 13-acetate (PMA)-differentiated THP-1 cells. METHODS AND RESULTS: After culturing the bacterium, the crude cell-free supernatant was fractionated on the basis of molecular weights using ultrafiltration. Also, a heat-killed and sonicated fraction was obtained from the biomass of the bacterial culture. All fractions were used to measure their anti-inflammatory effects on PMA-differentiated THP-1 cells following LPS stimulation by quantifying various cellular markers of inflammation. The results demonstrated that various L. reuteri PTCC 1655-derived fractions, especially the >100 kDa supernatant fraction decreased some of the inflammatory cytokines and mediators, including tumour necrosis factor-α, interleukin-1, nitric oxide, cyclooxygenase-2, matrix metalloproteinase-9 and interleukin-6, which are critical for the pathogenesis of some inflammatory diseases. CONCLUSION: It is concluded that the L. reuteri PTCC 1655-derived high molecular weight fractions significantly reduce inflammation and therefore could be appropriate candidates for future medical studies. SIGNIFICANCE AND IMPACT OF THE STUDY: Providing new insights about the significance of L. reuteri PTCC 1655-derived extracts and their potential to modulate inflammation.
AIMS: This study was done to investigate the anti-inflammatory effects of high molecular weight secretions from Limosilactobacillus reuteriPTCC 1655 probiotic bacteria on lipopolysaccharide (LPS)-stimulated phorbol 12-myristate 13-acetate (PMA)-differentiated THP-1 cells. METHODS AND RESULTS: After culturing the bacterium, the crude cell-free supernatant was fractionated on the basis of molecular weights using ultrafiltration. Also, a heat-killed and sonicated fraction was obtained from the biomass of the bacterial culture. All fractions were used to measure their anti-inflammatory effects on PMA-differentiated THP-1 cells following LPS stimulation by quantifying various cellular markers of inflammation. The results demonstrated that various L. reuteriPTCC 1655-derived fractions, especially the >100 kDa supernatant fraction decreased some of the inflammatory cytokines and mediators, including tumour necrosis factor-α, interleukin-1, nitric oxide, cyclooxygenase-2, matrix metalloproteinase-9 and interleukin-6, which are critical for the pathogenesis of some inflammatory diseases. CONCLUSION: It is concluded that the L. reuteriPTCC 1655-derived high molecular weight fractions significantly reduce inflammation and therefore could be appropriate candidates for future medical studies. SIGNIFICANCE AND IMPACT OF THE STUDY: Providing new insights about the significance of L. reuteriPTCC 1655-derived extracts and their potential to modulate inflammation.